Hepatologist Perspectives

Jeong Won Jang (The Catholic Univ. of Korea, Seoul)

Surgeon Perspectives

Norihiro Kokudo (National Center for Global Health and Medicine, Tokyo)

Interventional Oncologist Perspectives

Chien-An Liu (Taipei Veterans General Hospital, Taipei)

Radiation Oncologist Perspectives

Laura Dawson (Univ. of Toronto, Toronto)

Therapy of HCC: What Will Be the Next

Ann-Lii Cheng (National Taiwan Univ., Taipei)

Tumor Immune Microenvironment-Based Immunotherapy

Ghassan Abou-Alfa (Memorial Sloan-Kettering Cancer Center, New York)

Combination Immunotherapy with Anti-VEGF Multikinase Inhibitor

Richard Finn (The Univ. of California Los Angeles, CA)

Combination Immunotherapy with Anti-CTLA-4 Antibody

Thomas Yau (The Univ. of Hong Kong, Hong Kong)

Radiation and Checkpoint Blockade Immunotherapy

Andrew Sharabi (The Univ. of California San Diego, CA)

Update of Combined Hepatocellular-Cholangiocarcinoma

Matthew M. Yeh (Univ. of Washington School of Medicine, Seattle)

Progress of Chemotherapy and Targeted therapy in Cholangiocarcinoma

Masafumi Ikeda (National Cancer Center Hospital East, Tokyo)

Immunotherapy for Cholangiocarcinoma: Hope or Hype?

Andrew Zhu (Jiahui International Cancer Center, Shanghai)

Comparisons of Three Serum Biomarkers Alone and in Combination for Detection of HCC in Patients with Nonalcoholic Fatty Liver Disease: A Multicenter Case-Control Study

Tian Yang (Second Military Medical Univ., Shanghai)

Single-Cell RNA Sequencing Shows the Immunosuppressive Landscape and Tumor Heterogeneity of HBV-Associated HCC

Daniel Wai-Hung Ho (Univ. of Hong Kong, Hong Kong)

Liver Transplantation vs Partial Hepatectomy for Stage T2 Multifocal HCC: A Propensity-Score Matched Analysis

Kliment Bozhilov (Queen's Medical Center, Hawaii)

Combined Stereotactic Body Radiotherapy (SBRT) and Immunotherapy vs SBRT in Locally Advanced HCC: Propensity Score Matching Analysis

Chiang Chi Leung (Univ. of Hong Kong, Hong Kong)

Stereotactic Ablative Body Radiotherapy for Oligometastatic HCC: A Multi-Institutional Retrospective Study (KROG 20-04)

Tae Hyung Kim (Eulji Univ., Seoul)

Transcatheter Arterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable HCC (TACTICS-L) in Japan: Interim analysis

Issei Saeki (Yamaguchi Univ., Yamaguchi)

IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib by Baseline Varices Status in Patients with HCC

Philippe Merle (Hospital La Croix-Rousse, Lyon)

Nivolumab Plus Ipilimumab (N+I) as Neoadjuvant Therapy for Potentially Resectable HCC

Yung-Yeh Su (National Health Research Institute, Taiwan)